Preferred Label : lopinavir-ritonavir drug combination;
CISMeF synonym : aluvia; kaletra;
MeSH synonym : lopinavir and ritonavir drug combination; lopinavir and ritonavir; lopinavir, ritonavir drug combination;
Is substance : O;
Origin ID : C558899;
UMLS CUI : C0939237;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3186049/fr/veille-des-etudes-cliniques-publiees-pour-certains-medicaments-du-covid-19
2021
false
false
false
France
coronavirus infections
pneumonia, viral
review of literature
hydroxychloroquine
remdesivir
lopinavir-ritonavir drug combination
Clinical Studies as Topic
azithromycin
remdesivir
pneumonia, viral
coronavirus infections
pandemics
alanine
alanine
ribonucleotides
ritonavir
lopinavir
drug combinations
COVID-19
---
https://www.has-sante.fr/jcms/p_3215576/fr/kaletra
2020
false
false
false
France
lopinavir and ritonavir
evaluation of the transparency committee
lopinavir-ritonavir drug combination
ritonavir
lopinavir
drug combinations
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/kaletra-358.html
2020
false
false
false
Canada
treatment outcome
Evidence-Based medicine
lopinavir and ritonavir
drug evaluation
ritonavir
lopinavir
lopinavir-ritonavir drug combination
drug combinations
pneumonia, viral
coronavirus infections
pneumonia, viral
coronavirus infections
pandemics
drug combinations
COVID-19
---
https://ansm.sante.fr/actualites/medicaments-utilises-chez-les-patients-atteints-de-la-covid-19-une-surveillance-renforcee-des-effets-indesirables
2020
false
false
false
France
French
pharmacovigilance note
drug monitoring
Off-Label use
lopinavir-ritonavir drug combination
hydroxychloroquine
antiviral agents
cardiovascular diseases
pneumonia, viral
coronavirus infections
pandemics
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
pandemics
COVID-19
COVID-19
---
https://sfpt-fr.org/images/documents/STP/Recommandations_STP_ANRS_AC43_Pharmacologie_v2_26_03_20.pdf
2020
false
false
false
France
coronavirus infections
pneumonia, viral
lopinavir-ritonavir drug combination
guideline
hydroxychloroquine
drug monitoring
pandemics
pneumonia, viral
coronavirus infections
pandemics
ritonavir
lopinavir
drug combinations
COVID-19
---
https://www.ansm.sante.fr/actualites/lansm-securise-lacces-aux-traitements-plaquenil-et-kaletra-pour-les-patients-atteints-de-maladie-chronique
2020
false
false
false
France
French
hydroxychloroquine
lopinavir-ritonavir drug combination
arthritis, rheumatoid
hiv infections
lupus erythematosus, discoid
lupus erythematosus, cutaneous
Off-Label use
guidelines for drug use
chronic disease
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
pneumonia, viral
coronavirus infections
COVID-19
COVID-19
---
https://ansm.sante.fr/actualites/plaquenil-et-kaletra-les-traitements-testes-pour-soigner-les-patients-covid-19-ne-doivent-etre-utilises-qua-lhopital
2020
false
false
false
France
French
hydroxychloroquine
lopinavir-ritonavir drug combination
pharmacovigilance note
guidelines for drug use
hydroxychloroquine
arrhythmias, cardiac
drug monitoring
continuity of patient care
patients guideline
drug interactions
risk factors
coronavirus infections
pneumonia, viral
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
COVID-19
COVID-19
---
https://ansm.sante.fr/uploads/2020/10/15/20201015-putlopinavir-ritonavir-1.pdf
2020
false
false
false
France
French
Off-Label use
lopinavir-ritonavir drug combination
guidelines for drug use
antiviral agents
drug interactions
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
risk
antiviral agents
antiviral agents
pregnancy
coronavirus infections
pneumonia, viral
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
ritonavir
lopinavir
drug combinations
ritonavir
lopinavir
drug combinations
COVID-19
COVID-19
---
Maintien du remboursement dans les mêmes conditions
https://www.has-sante.fr/portail/jcms/c_2896415/en/kaletra
2018
true
France
French
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
infant, newborn
infant
child, preschool
lopinavir and ritonavir
adult
adolescent
child
hiv infections
anti-hiv agents
insurance, health, reimbursement
treatment outcome
HIV-1
drug therapy, combination
anti-hiv agents
administration, oral
evaluation of the transparency committee
ritonavir
lopinavir
drug combinations
ritonavir
lopinavir
drug combinations
---
Inscription d'une solution buvable adaptée à l’extension d’indication chez les jeunes
enfants et nourrissons âgés de 14 jours à 2 ans.
https://www.has-sante.fr/portail/jcms/c_2831910/fr/kaletra
2018
false
France
French
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
infant, newborn
infant
child, preschool
lopinavir and ritonavir
hiv infections
anti-hiv agents
insurance, health, reimbursement
treatment outcome
HIV-1
drug therapy, combination
anti-hiv agents
administration, oral
evaluation of the transparency committee
ritonavir
lopinavir
drug combinations
ritonavir
lopinavir
drug combinations
---
https://www.ema.europa.eu/medicines/human/EPAR/lopinavirritonavir-mylan
2016
false
United Kingdom
French
English
syndication feed
drugs, generic
Product containing lopinavir and ritonavir (medicinal product)
human immunodeficiency virus i infection
Product containing precisely lopinavir 100 milligram and ritonavir 25 milligram/1
each conventional release oral tablet (clinical drug)
Product containing precisely lopinavir 200 milligram and ritonavir 50 milligram/1
each conventional release oral tablet (clinical drug)
lopinavir
lopinavir
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
acquired immunodeficiency syndrome
adult
child
drug interactions
hiv protease inhibitors
anti-hiv agents
treatment outcome
drug evaluation
drug combinations
ritonavir
administration, oral
hiv infections
adolescent
anti-hiv agents
hiv protease inhibitors
drug therapy, combination
pregnancy
breast feeding
drug evaluation, preclinical
drug approval
HIV-1
ritonavir
package leaflet
summary of product characteristics
drug evaluation
lopinavir and ritonavir
drug combinations
drug combinations
---
https://www.ema.europa.eu/medicines/human/EPAR/Kaletra
2012
United Kingdom
French
English
syndication feed
lopinavir
lopinavir
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
acquired immunodeficiency syndrome
adult
child
drug interactions
hiv protease inhibitors
anti-hiv agents
treatment outcome
drug evaluation
drug combinations
ritonavir
tablets
capsules
pharmaceutical solutions
administration, oral
hiv infections
adolescent
anti-hiv agents
hiv protease inhibitors
drug therapy, combination
pregnancy
breast feeding
drug evaluation, preclinical
drug storage
drug labeling
drug approval
HIV-1
ritonavir
package leaflet
summary of product characteristics
drug evaluation
lopinavir and ritonavir
---
http://www.meddispar.fr/KALETRA-200-B-120/(type)/letter/(value)/K/(cip)/3400949409648
2011
France
French
lopinavir
lopinavir-ritonavir drug combination
drug combinations
ritonavir
administration, oral
drug prescriptions
legislation, drug
anti-hiv agents
drug information
lopinavir and ritonavir
---
http://www.meddispar.fr/medicaments/3844201
2008
France
French
lopinavir
lopinavir-ritonavir drug combination
ritonavir
legislation, drug
drug combinations
drug prescriptions
tablets
administration, oral
drug information
lopinavir and ritonavir
---
http://www.meddispar.fr/medicaments/3566819
2008
France
French
ritonavir
pharmaceutical solutions
administration, oral
drug combinations
drug prescriptions
legislation, drug
lopinavir
lopinavir-ritonavir drug combination
lopinavir and ritonavir
drug information
---
